|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THIAZIDES AND OTHER DIURETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
POTENTIAL FOR INCREASED RISK OF OTOTOXICITY WITH CONCOMITANT THERAPY, ESPECIALLY IN THE PRESENCE OF IMPAIRED RENAL FUNCTION ; AVOID CONCURRENT USE EXCEPT IN PRESENCE OF LIFE THERATENING SITUATIONS
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
CO-ADMINISTRATION MAY REDUCE THE NATRIURETIC AND ANTIHYPERTENSIVE EFFECTS OF FRUSEMIDE IN SOME PATIENTS BY INHIBITING PROSTAGLANDIN SYNTHESIS
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE ANTAGONISE THE SKELETAL MUSCLE RELAXING EFFECT OF TUBOCURARINE LIKE NEUROMUSCULAR BLOCKING AGENTS
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CO-ADMINISTRATION WITH CORTICOSTEROIDS MAY INCREASE THE RISK OF HYPOKALEMIA
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
DIURETICS REDUCE LITHIUMS RENAL CLEARANCE AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
MUTUAL IMPAIRMENT OF EXCRETION & AN INCREASE IN SERUM LEVELS MUST BE CONSIDERED WHEN QUINOLONE IS GIVEN WITH OTHER DRUG THAT ALSO UNDERGO RENAL TUBULAR EXCRETION PARTICULARLY WHEN IN HIGH DOSES, LIKE FRUSEMIDE, PROBENECID, CIMETIDIN, METHOTREXATE
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
INCREASED RISK OF HYPOKALEMIA
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
NON POTASSIUM SPARING DIURETICS MAY CAUSE UNPRECEDENTED HYPOKALEMIA
|
CO-ADMINISTRATION HAS RESULTED IN THROMBOCYTOPENIA
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CO-ADMINISTRATION WITH CORTICOSTEROIDS MAY INCREASE THE RISK OF HYPOKALEMIA
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CO-ADMINISTRATION WITH CORTICOSTEROIDS MAY INCREASE THE RISK OF HYPOKALEMIA
|
COMBINATION OF FRUSEMIDE AND ASPIRIN TEMPORARILY REDUCED CREATININE CLEARANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY ; CO-ADMINISTRATION IN PATIENTS RECEIVING HIGH DOSES OF SALICYLATES MAY EXPERIENCE SALICYLATE TOXICITY
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
POTASSIUM-DEPLETING DIURETICS CAN CAUSE HYPOKALEMIA AND CO-ADMINISTRATION CAN RESULT IN DIGITALIS TOXICITY
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
INCREASED RISK OF HYPOKALEMIA
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|